INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK CITY, NY / ACCESS Newswire / October 23, 2026 /Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether J&J and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On October 13, 2026, J&J reported its financial results for the third quarter of 2026, which including GAAP net earnings of only $210 million ($0.09 per share) due to multi-billion dollar special charges tied to its ongoing talc litigation settlement. J&J also reported a pronounced, successive revenue miss inside its MedTech business segment, which grew by only 2.5% ($8.64 billion) due to escalating international pricing constraints in China and acute geopolitical disruptions in the Middle East.
On this news, J&J 's stock price fell $15.12 per share, or 5.73%, to close at $248.61 per share on October 13, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:Pomerantz LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
